Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?

Core Insights - The U.K.'s NICE has recommended Autolus Therapeutics' Aucatzyl for use in the NHS for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia [1][2] - Aucatzyl will be available through routine commissioning by the NHS, with plans for launch in England and Wales [2] - The MHRA granted conditional marketing authorization for Aucatzyl based on the FELIX study results [3] Company Developments - Autolus Therapeutics is preparing to launch Aucatzyl imminently in England and Wales and is pursuing access through the Scottish Medical Consortium [2] - The stock price of Autolus Therapeutics was reported at $1.38, with a notable increase of 10.48% to $1.37 at the time of publication [5][7] Product Information - Aucatzyl (obecabtagene autoleucel) is an autologous CD19 CAR T cell therapy designed for treating specific types of leukemia [3] - The therapy targets adult patients (≥26 years) suffering from relapsed or refractory B-cell precursor acute lymphoblastic leukemia [1][3]